This process indirectly activates cytotoxic T lymphocytes, crucial for targeting and destroying tumor cells.[41] However, its involvement in the NF-κB signaling pathway also suggests that TRANCE could facilitate cancer progression in some contexts, which contrasts with its role in bone resorption and tumor growth in diseases like multiple myeloma.[42] These insights highlight CXCL9 and TRANCE as a nuanced prognostic marker, emphasizing the need for further research to fully understand its therapeutic potential in oral cancer. The gene discussed is NFKB1; the disease is neoplasm.